

George T Grossberg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3110431/publications.pdf>

Version: 2024-02-01

53
papers

3,119
citations

218677

26
h-index

197818

49
g-index

57
all docs

57
docs citations

57
times ranked

4465
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Alcohol, Drugs, and Baby Boomers. <i>Clinics in Geriatric Medicine</i> , 2022, 38, xiii-xiv. | 2.6 | 1 |
| 2 | Comparison of the Impact of the Mediterranean Diet, Anti-Inflammatory Diet, Seventh-Day Adventist Diet, and Ketogenic Diet Relative to Cognition and Cognitive Decline. <i>Current Nutrition Reports</i> , 2022, 11, 161-171. | 4.3 | 4 |
| 3 | Evaluation of rivastigmine in Alzheimer's disease. <i>Neurodegenerative Disease Management</i> , 2021, 11, 35-48. | 2.2 | 45 |
| 4 | AVP-786 as a promising treatment option for Alzheimer's Disease including agitation. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 783-795. | 1.8 | 19 |
| 5 | Pharmacotherapy for Frontotemporal Dementia. <i>CNS Drugs</i> , 2021, 35, 425-438. | 5.9 | 9 |
| 6 | Psychosis in Parkinson's Disease: Current Treatment Options and Impact on Patients and Caregivers. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2021, 34, 274-279. | 2.3 | 16 |
| 7 | Impact of agitation in long-term care residents with dementia in the United States. <i>International Journal of Geriatric Psychiatry</i> , 2021, 36, 1959-1969. | 2.7 | 6 |
| 8 | Diagnostic Accuracy of the SLU AMSAD Scale for Depression in Older Adults Without Dementia. <i>Journal of the American Medical Directors Association</i> , 2020, 21, 665-668. | 2.5 | 1 |
| 9 | Dietary Interventions to Prevent or Delay Alzheimer's Disease: What the Evidence Shows. <i>Current Nutrition Reports</i> , 2020, 9, 210-225. | 4.3 | 20 |
| 10 | Deciphering Alzheimer's disease: predicting new therapeutic strategies via improved understanding of biology and pathogenesis. <i>Expert Opinion on Therapeutic Targets</i> , 2020, 24, 859-868. | 3.4 | 11 |
| 11 | An evaluation of hydromethylthionine as a treatment option for Alzheimer's disease. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 619-627. | 1.8 | 11 |
| 12 | An update on the utility and safety of cholinesterase inhibitors for the treatment of Alzheimer's disease. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 147-157. | 2.4 | 97 |
| 13 | Testing the Cognitive Reserve Index Questionnaire in an Alzheimer's Disease Population. <i>Journal of Alzheimer's Disease Reports</i> , 2020, 4, 513-524. | 2.2 | 7 |
| 14 | Eating disturbances in the elderly: A geriatric-psychiatric perspective. <i>Nutrition and Healthy Aging</i> , 2019, 5, 185-198. | 1.1 | 7 |
| 15 | Use of Cholinesterase Inhibitors in Non-Alzheimer's Dementias. <i>Drugs and Aging</i> , 2019, 36, 719-731. | 2.7 | 27 |
| 16 | Impact of Antidepressant Use on the Trajectory of Alzheimer's Disease: Evidence, Mechanisms, and Therapeutic Implications. <i>CNS Drugs</i> , 2019, 33, 17-29. | 5.9 | 7 |
| 17 | Rational deprescribing in the elderly. <i>Annals of Clinical Psychiatry</i> , 2019, 31, 144-152. | 0.6 | 19 |
| 18 | An update on the safety of current therapies for Alzheimer's disease: focus on rivastigmine. <i>Therapeutic Advances in Drug Safety</i> , 2018, 9, 171-178. | 2.4 | 98 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | An evaluation of memantine ER + donepezil for the treatment of Alzheimer's disease. Expert Opinion on Pharmacotherapy, 2018, 19, 1711-1717. | 1.8 | 41 |
| 20 | The cholinergic system in the pathophysiology and treatment of Alzheimer's disease. Brain, 2018, 141, 1917-1933. | 7.6 | 1,008 |
| 21 | The role of 5 HT6-receptor antagonists in Alzheimer's disease: an update. Expert Opinion on Investigational Drugs, 2018, 27, 523-533. | 4.1 | 84 |
| 22 | Strategies for Continued Successful Treatment in Patients with Alzheimer's Disease: An Overview of Switching Between Pharmacological Agents. Current Alzheimer Research, 2018, 15, 964-974. | 1.4 | 9 |
| 23 | Emerging chemical therapies targeting 5-hydroxytryptamine in the treatment of Alzheimer's disease. Expert Opinion on Emerging Drugs, 2017, 22, 101-105. | 2.4 | 16 |
| 24 | Recent Progress in the Pharmacotherapy of Alzheimer's Disease. Drugs and Aging, 2017, 34, 811-820. | 2.7 | 46 |
| 25 | A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer's disease. Drug Design, Development and Therapy, 2016, Volume 10, 3267-3279. | 4.3 | 77 |
| 26 | The Saint Louis University Mental Status Examination Is Better than the Mini-Mental State Examination to Determine the Cognitive Impairment in Turkish Elderly People. Journal of the American Medical Directors Association, 2016, 17, 370.e11-370.e15. | 2.5 | 27 |
| 27 | Amyloid and Tau Biomarkers in Subjective Cognitive Impairment. Journal of Alzheimer's Disease, 2015, 47, 1-8. | 2.6 | 39 |
| 28 | The Use of Cholinesterase Inhibitors Across All Stages of Alzheimer's Disease. Drugs and Aging, 2015, 32, 537-547. | 2.7 | 96 |
| 29 | The Pharmacology and Clinical Use of the Antidepressants Vilazodone, Levomilnacipran, and Vortioxetine for Depression in the Elderly. Current Geriatrics Reports, 2015, 4, 301-311. | 1.1 | 2 |
| 30 | Brain Health: The Importance of Recognizing Cognitive Impairment: An IAGG Consensus Conference. Journal of the American Medical Directors Association, 2015, 16, 731-739. | 2.5 | 222 |
| 31 | P1-173: IDEOMOTOR LIMB APRAXIA IN INDIVIDUALS WITH ALZHEIMER'S DISEASE DEMENTIA (ILIAD). , 2014, 10, P363-P363. | | 0 |
| 32 | P1-370: EFFICACY AND TOLERABILITY OF MEMANTINE EXTENDED RELEASE ADDED TO STABLE DONEPEZIL REGIMEN IN INDIVIDUALS WITH MODERATE TO SEVERE ALZHEIMER'S DISEASE: SUBSET ANALYSIS OF A RANDOMIZED CLINICAL TRIAL. , 2014, 10, P450-P450. | | 4 |
| 33 | Cognitive Deficit Reversal as Shown by Changes in the Veterans Affairs Saint Louis University Mental Status (SLUMS) Examination Scores 7.5 Years Later. Journal of the American Medical Directors Association, 2014, 15, 687.e5-687.e10. | 2.5 | 39 |
| 34 | Brain Games to Slow Cognitive Decline in Alzheimer's Disease. Journal of the American Medical Directors Association, 2014, 15, 536-537. | 2.5 | 16 |
| 35 | P1-023: EFFICACY AND SAFETY OF OVER-THE-COUNTER MEMORY-ENHANCING SUPPLEMENTS: WHAT THE EVIDENCE SHOWS. , 2014, 10, P312-P312. | | 0 |
| 36 | Rivastigmine From Capsules to Patch. primary care companion for CNS disorders, The, 2014, 16, . | 0.6 | 20 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | The Safety, Tolerability, and Efficacy of Once-Daily Memantine (28Âmg): A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients with Moderate-to-Severe Alzheimerâ€™s Disease Taking Cholinesterase Inhibitors. <i>CNS Drugs</i> , 2013, 27, 469-478. | 5.9 | 128 |
| 38 | Orexigenic agents in geriatric clinical practice. <i>Aging Health</i> , 2013, 9, 49-65. | 0.3 | 3 |
| 39 | A 24â€Week, Randomized, Controlled Trial of Rivastigmine Patch 13.3Âmg/24Âh Versus 4.6Âmg/24Âh in Severe Alzheimer's Dementia. <i>CNS Neuroscience and Therapeutics</i> , 2013, 19, 745-752. | 3.9 | 63 |
| 40 | Combination Therapy for Alzheimerâ€™s Disease. <i>Drugs and Aging</i> , 2011, 28, 539-546. | 2.7 | 75 |
| 41 | Geriatric psychiatry--an emerging specialty. <i>Missouri Medicine</i> , 2010, 107, 401-5. | 0.3 | 1 |
| 42 | Memantine Therapy of Behavioral Symptoms in Community-Dwelling Patients with Moderate to Severe Alzheimerâ€™s Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2009, 27, 164-172. | 1.5 | 50 |
| 43 | Safety and Tolerability of the Rivastigmine Patch. <i>Alzheimer Disease and Associated Disorders</i> , 2009, 23, 158-164. | 1.3 | 39 |
| 44 | Pharmacology of Acetylcholinesterase Inhibitors and N-methyl-D-aspartate Receptors for Combination Therapy in the Treatment of Alzheimer's Disease. <i>Journal of Clinical Pharmacology</i> , 2006, 46, 8S-16S. | 2.0 | 69 |
| 45 | Effect of rivastigmine in the treatment of behavioral disturbances associated with dementia: review of neuropsychiatric impairment in Alzheimer's disease. <i>Current Medical Research and Opinion</i> , 2005, 21, 1631-1639. | 1.9 | 21 |
| 46 | Rivastigmine for Alzheimerâ€™s disease. <i>Expert Review of Neurotherapeutics</i> , 2005, 5, 563-580. | 2.8 | 35 |
| 47 | Cholinesterase Inhibitors for the Treatment of Alzheimer's Disease:. <i>Current Therapeutic Research</i> , 2003, 64, 216-235. | 1.2 | 232 |
| 48 | Management of Alzheimer's Disease. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2003, 58, M331-M353. | 3.6 | 65 |
| 49 | The ABC of Alzheimer's Disease: Behavioral Symptoms and Their Treatment. <i>International Psychogeriatrics</i> , 2002, 14, 27-49. | 1.0 | 49 |
| 50 | Review of rivastigmine and its clinical applications in Alzheimerâ€™s disease and related disorders. <i>Expert Opinion on Pharmacotherapy</i> , 2001, 2, 653-666. | 1.8 | 31 |
| 51 | Behavioral and Psychological Symptoms of Dementia as a Risk Factor for Nursing Home Placement. <i>International Psychogeriatrics</i> , 2000, 12, 59-62. | 1.0 | 68 |
| 52 | Drug-Induced Seizures in the Elderly. <i>Drugs and Aging</i> , 1995, 7, 38-48. | 2.7 | 36 |
| 53 | Pharmacotherapy for Alzheimerâ€™s disease: whatâ€™s new on the horizon?. <i>Expert Opinion on Pharmacotherapy</i> , 0, , 1-19. | 1.8 | 1 |